From November 2021 to July 2022, patients with internal hemorrhoids seeking treatment were enrolled according to the following criteria:~Age 18 to 75, men and women;~Patients with clinical symptoms of degree I-Ⅲ internal hemorrhoids confirmed after medical history collection, clinical examination or colonoscopy;~The patient was willing to receive minimally invasive treatment for internal hemorrhoids and sign informed consent by himself or his legal agent.~Exclusion criteria are as follows:~age <18 or> 75;~External hemorrhoids or mixed hemorrhoids;~Ⅳ degree of hemorrhoid~Unsymptomatic internal hemorrhoids;~Internal hemorrhoids were combined with complications such as chimerism, thrombosis, ulceration, or infection;~Poor basic conditions can not tolerate endoscopic treatment, such as serious cardiovascular and cerebrovascular diseases, respiratory dysfunction, liver and kidney failure, mental disorders, etc.;~There are other serious diseases involving the rectum and anus, such as anal fistula, perianal infection, anal stenosis, inflammatory bowel disease activity period, colorectal tumors, etc.;~Patients with severe coagulation dysfunction or long-term oral anticoagulant drugs or antiplatelet aggregation drugs without withdrawal;~Women in pregnancy or puerperium;~Sclerotic with allergy patient , such as polycininol, etc;~Previous history of endoscopic treatment of hemorrhoid disease, surgical history or other low rectal and anal surgery history;~The patient was unwilling to receive endoscopic treatment for internal hemorrhoids, and himself or his legal agent refused to sign the informed consent form.
This study is a prospective, multicentre, and randomized-controlled clinical study.The researchers wanted to explore the optimal treatment regimen for soft hemorrhoid within I-Ⅲ degrees by evaluating and comparing the effectiveness, safety and cost effect ratio of sclerosing injection and rubber lap ligation in patients with different internal hemorrhoid scores